Sign up to save your podcastsEmail addressPasswordRegisterOrContinue with GoogleAlready have an account? Log in here.
Welcome to Few & Far Between! Melissa Alesse, President of Biorasi, is your host for fascinating conversations - from clinical research and policymakers to biotech innovators and industry leaders.... more
FAQs about Few & Far Between: How Biotech Gets Built:How many episodes does Few & Far Between: How Biotech Gets Built have?The podcast currently has 73 episodes available.
September 17, 2025Episode 60: Part Two: Yochi Slonim, Co-Founder and CEO at Anima BiotechCan AI see and talk to human cells? Find out in today's episode of the Biorasi Few & Far Between podcast.Host Chris O'Brien welcomes Yochi Slonim, Co-Founder and CEO at Anima Biotech, to the podcast. Get ready for part two of this special two-part episode as we touch on smarter LLMs, evolved AI agents, and connecting data to real-world biology.Okay, let's start the podcast!...more43minPlay
September 03, 2025Episode 59, Part One: Yochi Slonim, Co-Founder and CEO at Anima BiotechWhat do software bugs and human cells have in common? Find out in today's episode of the Biorasi Few & Far Between podcast.Host Chris O'Brien welcomes Yochi Slonim, Co-Founder and CEO at Anima Biotech, to the podcast. Tune in to part one of this special two-part episode as we double-click on #AIagents, building neural networks, and syncing visual biology with real-world biology.Okay, let's start the podcast!...more44minPlay
August 14, 2025Episode 58: Jerry McLaughlin, CEO and Board Member at Life BiosciencesHow does a biopharma background prepare you for the biotech playground?Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Jerry McLaughlin, CEO and Board Member at Life Biosciences, for an insightful discussion on cellular rejuvenation, working hand in hand with a board of directors, and knowing when to walk away from a clinical trial.Tune in today!...more45minPlay
July 22, 2025Episode 57: Jim Brown, DVM, President and CEO of DURECT CorporationIs the epigenome the "software" of the cell nucleus?Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Jim Brown, President and CEO of DURECT Corporation, for a conversation on the importance of a pharmacoeconomic strategy, developing new treatments for alcohol associated hepatitis, and moving beyond what a single individual can do in clinical research.Tune in today!...more45minPlay
July 15, 2025Episode 56, Part Two: Michael Tolentino, MD, Co-Founder and Head Scientific Consultant, Aviceda TherapeuticsHow do experienced troubleshooters solve a difficult problem? By asking the right questions first!Welcome back to part two of our conversation with Michael Tolentino, MD, Co-Founder and Head Scientific Consultant at Aviceda Therapeutics. Join host Chris O'Brien as he and Dr. Tolentino, explore the traits of top problem solvers, the power of communication, and how silos and "bad apples" can undermine today's biotechs.Okay, let's start the podcast!...more40minPlay
July 09, 2025Episode 55: Julio G. Martinez-Clark, CEO and Co-Founder at bioaccess®How much do you know about clinical trials in Latin America? Take a deep dive with us as we explore the benefits and risks of running studies in this region.In our latest episode of the Biorasi Few & Far Between podcast, host Chris O'Brien welcomes Julio G. Martinez-Clark, CEO and Co-Founder at bioaccess®. Tune in as we spotlight the advantages of running studies in #LATAM - from data quality to speed to approval....more39minPlay
May 28, 2025Episode 54, Part One: Michael Tolentino, MD, Co-Founder and Head Scientific Consultant, Aviceda TherapeuticsThe challenge? Decoding the human immune system. Get ready to meet the top challenger on today's episode of the Biorasi Few & Far Between podcast.Host Chris O'Brien welcomes Michael Tolentino, MD, Co-Founder and Head Scientific Consultant at Aviceda Therapeutics, to the podcast. Tune in to part one of this special two-part episode as we explore Michael's start in ophthalmology, groundbreaking treatments in intra-retinal therapy, and the importance of being a great communicator.Okay, let's start the podcast! ...more46minPlay
April 29, 2025Episode 53: Frank David, Founder and Managing Director, PharmagellanHow do mission, vision, and data analysis fit into today's biotech goals?Host Chris O'Brien welcomes Frank David, Founder and Managing Director of Pharmagellan to the podcast. Tune in as we explore R&D strategy, de-risking tactics, and how to think about valuation.Listen in to the latest episode of the Biorasi Few & Far Between podcast today! ...more51minPlay
April 23, 2025Episode 52: Joshua Kresh, Emily Michiko Morris, and Mark Schultz, IPPIHow does a biotech balance great science with IP security to tell their story? Find out on today's episode of the Few & Far Between podcast!Host Chris O'Brien welcomes Joshua Kresh, Emily Michiko Morris, and Mark Schultz from IPPI: The Intellectual Property Policy Institute. Tune in for a fascinating discussion on the dos and don'ts of IP protection.Listen to the latest episode today!...more53minPlay
April 03, 2025Episode 51: Dan Oliver, CEO and Founder, Rejuvenate BioHow do you turn back the epigenetic clock for humans and their animal companions? Host Chris O'Brien welcomes Dan Oliver, CEO and Founder of Rejuvenate Bio, to the podcast. Tune in as we take a deep dive into parallel clinical trials designed to address chronic, age-related diseases in people and their pets. Plus, we'll zoom in on the right corporate structure for biotech products and the benefits of brainstorming.Listen in to the latest episode of the Few & Far Between podcast today! ...more56minPlay
FAQs about Few & Far Between: How Biotech Gets Built:How many episodes does Few & Far Between: How Biotech Gets Built have?The podcast currently has 73 episodes available.